Despite advances in symptomatic therapies such as dopamine replacement therapy and deep brain stimulation, disease-modifying therapies have so far been found that could slow or stop neurodegeneration in PD patients [55]
This would reduce glomerular hydrostatic pressure and initially decrease GFR, an effect that is observed with SGLT2 treatment, but in the long run this decrease in GFR protects the kidney from damage resulting in improved kidney function long-term (139)
Ozempic is first GLP-1 drug FDA-approved for kidney disease Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes
Demand Drivers in the Market Patients need clear injection instruction before the first dose
GHRP-2 has a much milder effect on hunger, making it better suited for recomp or fat loss phases where caloric intake needs to be controlled
AOD-9604: The Fat-Burning Peptide Explained Abstract AOD-9604 is a synthetic peptide derived from the 177191 amino acid sequence of human growth hormone (hGH)
